TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00298558

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Training
Description: Memory, Reasoning, or Speed of Processing cognitive training interventions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Memory, Reasoning, or Speed of Processing cognitive training interventions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Memory, Reasoning, or Speed of Processing cognitive training interventions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Memory, Reasoning, or Speed of Processing cognitive training interventions
Study: NCT04045028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab/rHuPH20
Description: Administered by SC injection 1800 mg/30,000 U rHuPH20 weekly for a total of 6 doses, then every 3 weeks for a total of 16 doses (first dose given at Week 7), then every 4 weeks from Week 55 onward until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab/rHuPH20
Description: Administered by SC injection 1800 mg/30,000 U rHuPH20 weekly for a total of 6 doses, then every 3 weeks for a total of 16 doses (first dose given at Week 7), then every 4 weeks from Week 55 onward until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered for a total of 8 doses. Rituximab will be administered by IV infusion for the first dose at a dose of 375 mg/m\^2. After administration of at least one full infusion of IV rituximab, the SC formulation of rituximab (rituximab and rHuPH20) may be used for the remaining doses per institutional guidelines. SC rituximab will be administered at a dose of 1400 mg rituximab/23400 U rHuPH20 once weekly (QW).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Administered by IV infusion at a fixed dose of 1200 mg Q3W
Study: NCT02545088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Assistive Limb (HAL)
Description: Intensive gait training with Hybrid Assistive Limb (HAL) is performed 1 session/day, 3 days/week for 6 weeks and each session will not exceed 60 min of effective walking time with HAL. In addition, each session will include conventional gait training that will not exceed 30 min effective training time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1st control group
Description: Conventional gait training performed 1 session/day, 3 days/week for 6 weeks that will not exceed 1h 30 min effective training time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2nd control group
Description: The 2nd control group will not receive an intervention.
Study: NCT04002102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OLP treatment
Description: Receive two open-label placebo pills twice a day after randomization. Will receive for 21 days and then stop. It will include educational materials and positive expectancy.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Remain in standard care after randomization and educational materials.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expectancy Group
Description: Educational materials and positive expectancy orientation via Zoom or telephone
Study: NCT04237116

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Arm - secukinumab
Description: secukinumab 300mg s.c. weekly in first 4 weeks, followed by q4w up to Week 20; and placebo 300mg s.c. at weeks 13, 14 and 15 to maintain the blind

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Arm - placebo
Description: placebo 300 mg s.c. weekly in first 4 weeks, followed by q4w up to Week 8; and secukinumab 300 mg s.c. weekly for 4 weeks starting at Week 12, followed by q4w up to Week 20
Study: NCT01073111

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: zotarolimus-eluting stent (ENDEAVOR®)
Description: zotarolimus-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus-eluting stents (CYPHER SELECT® PLUS)
Description: sirolimus-eluting stents

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: everolimus-eluting stents (PROMUS®)
Description: everolimus-eluting stents
Study: NCT01342016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus capsule
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus placebo
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leflunomide tablet
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leflunomide placebo
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: oral
Study: NCT02689037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty and stenting
Description: Surgeons will plant stents after vascular angioplasty in target ICAS vessels within 5 days after randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin plus clopidogrel
Description: aspirin 100mg daily and clopidogrel 75mg daily for 90 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel
Description: aspirin 100mg daily and clopidogrel 75mg daily for 90 days
Study: NCT05589467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH-FP
Description: Dash diet with only fried potatoes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH-NFP
Description: Dash diet with only non-fried potatoes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Dash diet with no potatoes
Study: NCT02841904

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Confocal LASER Endomicroscopy
Description: Patients scheduled for bladder endoscopic surgery under general anesthesia are offered to be included in our study. The suspicious mucosal areas are marked then examined with CLE. Tissue samples are taken based on the usual standard criterias. The samples are evaluated microscopically and compared with the results of the CLE technique. A single surgeon performs all surgeries. Biopsies are anlysed by a pathologist from Herlev and Gentofte Hospital's Pathology Department, which is affiliated CLE- study.

Intervention type: DEVICE
Group type: OTHER
Intervention: Confocal LASER Endomicroscopy
Description: Patients scheduled for bladder endoscopic surgery under general anesthesia are offered to be included in our study. The suspicious mucosal areas are marked then examined with CLE. Tissue samples are taken based on the usual standard criterias. The samples are evaluated microscopically and compared with the results of the CLE technique. A single surgeon performs all surgeries. Biopsies are anlysed by a pathologist from Herlev and Gentofte Hospital's Pathology Department, which is affiliated CLE- study.
Study: NCT03461588

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: free-breathing
Description: patients are irradiated to whole breast +- regional nodal areas with free-breathing technique after breast conserving surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: deep inspiratory breath-holding
Description: patients are irradiated to whole breast +- regional nodal areas with deep inspiratory breast-holding technique after breast conserving surgery
Study: NCT04078906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: n3-LCPUFA enriched Intravenous Lipid Emulsion
Description: To start from D0 at 1g/kg/day and increase by 1 g/kg daily till reaching 3 g/kg/day.
Study: NCT00721968

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glaucoma Stent Surgery (GTS400 Stent)
Description: ab interno trabecular bypass stent surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cataract surgery alone
Description: Cataract surgery alone
Study: NCT02930018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerinetide (NA-1), 2.6 mg/kg
Description: Single intravenous infusion of nerinetide over 10 ± 1 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: Placebo
Study: NCT06592456

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chickenpox Vaccines
Description: The vaccines require reconstitution with the provided sterile water for injection nd should be shaken well before use. Each human dose (0.5 ml) contains at least 3.3 log PFU of VZV.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Chickenpox Vaccines
Description: The vaccines require reconstitution with the provided sterile water for injection nd should be shaken well before use. Each human dose (0.5 ml) contains at least 3.3 log PFU of VZV.
Study: NCT03593746

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical training
Description: Type 2 diabetic patients will be subjected to different types of physical training (high intensity interval training or combined training).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Type 2 diabetic patients will be subjected to different types of physical training (high intensity interval training or combined training).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Type 2 diabetic patients will be subjected to different types of physical training (high intensity interval training or combined training).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical training
Description: Type 2 diabetic patients will be subjected to different types of physical training (high intensity interval training or combined training).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Light-Emitting Diode (LED) therapy
Description: Type 2 diabetic patients will be subjected to Light-Emitting Diode (LED) therapy (active or sham).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light-Emitting Diode (LED) therapy
Description: Type 2 diabetic patients will be subjected to Light-Emitting Diode (LED) therapy (active or sham).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light-Emitting Diode (LED) therapy
Description: Type 2 diabetic patients will be subjected to Light-Emitting Diode (LED) therapy (active or sham).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Light-Emitting Diode (LED) therapy
Description: Type 2 diabetic patients will be subjected to Light-Emitting Diode (LED) therapy (active or sham).
Study: NCT02786394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH
Description: REACH is a lifestyle intervention program which aims to reduce sedentary behaviour, increase physical activity, and increase strength and balance. The REACH program is comprised of six sessions which include evidence-based education, behaviour change theory, and activity instruction. REACH also teaches goal setting techniques, mindfulness, and encourages active community engagement. In this study we are running the REACH program for women aged 55 and older alongside a supplementary optional walking program run by SportMedBC.
Study: NCT04259814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech-language therapy (SLT)
Description: Age-appropriate play activities with speech-language pathologist (SLP) to elicit speech, using stimulation strategies including but not limited to recasts, expansion, parallel talk, interactive modeling, communication temptations, and phrase completions. Activities will include an age-appropriate story, pretend play (i.e., house with people, playing with a baby doll), an assembly task (i.e., building blocks, making pretend pizza), and a highly motivating, clinician-controlled activity (i.e., blowing bubbles, swing, pushing cars down a ramp).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy (mCIMT)
Description: Participants will wear a removable cast and an occupational therapist will be present during therapy to focus on facilitating play with the affected arm.
Study: NCT04259099

Intervention type: OTHER
Intervention: Testing the Quality of Life Questionnaire of the European Foundation for Osteoporosis-31(QUALEFFO-31)
Description: Administer the questionnaires to 150 participants to classify their status of quality of life.
Study: NCT01378585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1033
Description: 3 x 490 mg DLBS1033 daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 x 1 tablet daily
Study: NCT04176471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Therapeutic hypothermia involves use of a servo-controlled device and blanket to lower the core body temperature by 3°C for 72 hours followed by a period of re-warming in which the temperature is increased by 0.5°C per hour for 6 hours until normothermia is achieved.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normothermia
Description: Normothermia will be achieved using the same servo-controlled device and blanket to assure normothermia of the control arm. The goal temperature for normothermia is 36.5-37.3°C for 72 hours.
Study: NCT04070872

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D laparoscope
Description: For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2D laparoscope
Description: For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
Study: NCT04359316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: This Drug will be used in all arms as mandated by our governmental guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: This Drug will be used in all arms as mandated by our governmental guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: This will be drug only used in the intervention arm of our study, designed mainly to assess the additional efficacy and safety of Azithromycin in COVID-19 patients.
Study: NCT01921595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Valanced salt colloid
Description: Maximum dose : 30ml/kg, IV, The infusion of valanced salt colloid is started at bleeding and continued until reach at maximum dose

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Valanced salt crystalloid group
Description: Maximum dose : 30ml/kg, IV, The infusion of valanced salt crystalloid is started at bleeding and continued until reach at maximum dose
Study: NCT00755183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone ophthalmic solution
Description: testosterone ophthalmic solution for 128 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle of testosterone ophthalmic solution
Description: vehicle of testosterone ophthalmic solution for 128 days
Study: NCT01547078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilized Plasma
Description: Licensed plasma that has been lyophilized.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Plasma
Description: Plasma that has been authorized for transfusion.
Study: NCT02398435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tadekinig alfa (recombinant human IL-18 binding protein)
Description: Patients received the study treatment three times a week subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tadekinig alfa (recombinant human IL-18 binding protein)
Description: Patients received the study treatment three times a week subcutaneously.
Study: NCT04674423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Tenofovir Alafenamide treatment for 144 weeks
Study: NCT00110747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)
Description: S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Peel
Description: Peel was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
Study: NCT02397161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG biofeedback mental attention-neuromuscular training
Description: Mental attention training using EEG biofeedback and neuromuscular training using physio-therapeutic exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular training
Description: Neuromuscular training using physio-therapeutic exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG biofeedback mental attention training
Description: Mental attention training using EEG biofeedback
Study: NCT01911494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Engagement
Description: The primary objective of the community engagement activities in CLIP will be to create awareness and action around the prevention of maternal morbidity and mortality due to pre-eclampsia/eclampsia. Community engagement involves the collective action of individuals, families, religious leaders, policy makers,

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PIERS on the Move mHealth decision aid
Description: This mHealth application is to be used by community health workers in intervention clusters to guide collection of relevant clinical data during antenatal visits. This clinical data is used to generate a risk estimate for any women with hypertension based on the miniPIERS (Pre-eclampsia Integrated Estimate of Risk) clinical risk prediction model. This risk estimate in combination with other pre-defined treatment triggers (severe hypertension (\>160mmHg systolic) or proteinuria (\>3+ dipstick); absence of fetal movements for greater than 12 hours; signs of recent stroke of seizure) are collected in the app and based on this data recommendations for care of the woman are provided.
Study: NCT01083771

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Oil
Description: Minimum of 3 tablespoon of olive oil per day
Study: NCT04446884

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived mesenchymal stem cells
Description: Autologous adipose-derived mesenchymal stem cells mixed with collagen solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment according to the Clinical protocols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment according to the Clinical protocols
Description: Standard treatment according to the Clinical protocols
Study: NCT04089995

Intervention type: OTHER
Intervention: data collection
Description: No intervention
Study: NCT01323101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline 40mg, 100mg, 200mg tablet once daily, or no drug for 28 days.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No doxycycline
Study: NCT04188561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra articular injection Group
Description: Patients included in the study had been received 2 ml high molecular weight (1.476 x 106 average Daltons) hyaluronic acid with concentration of 22mg/ml (OPTIVISC UK hyaluronic acid for intra articular injection). Platelet rich plasma is arranged by withdrawing 10 ml of patient's personal venous blood, anticoagulant is added, and centrifuged by duo-spin method, at the rate of 3500 rpm for five minutes then injected twice with 2 weeks interval. 3 distinct layers are produced by the end of the centrifugation: plasma, buffy coat (platelet) and RBCs, about 3 - 3.5 ml of PRP is produced~at the end with platelet concentration of 1.4 - 1.6 million/μl on average.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Group
Description: Thermal radiation is done by Neurotherm 2000 (Neurotherm NT 2000 Radiofrequency (RF) Generator is a four electrode pain management (RF) generator for interventional pain management procedures. Neurotherm's newest system offers accurate independent controls of each electrode through the touch screen interface and output control knobs.), Patients from the radiofrequency (RF) group had been placed in the supine position and their knee will be supported by a small pillow placed beneath the popliteal fossa. Fluoroscopic images of knee joint had been obtained. Possible locations of genicular nerves had been determined on the lateral, medial aspects of the lower end of the femoral bone and on the medial aspect of the tibia, under fluoroscopic guidance.
Study: NCT01411046

Intervention type: DIAGNOSTIC_TEST
Intervention: Synacthen test
Description: 250 microg Synacthen test, performed fasting, in the morning, starting between 08·00 and 10·30 h, after an overnight fast and a prednisolone pause of approximately 48 hours (depending on normal dose administration time).
Study: NCT00553878

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dutasteride
Description: dutasteride 0.5mg capsule daily until serum PSA rises to 5ng/ml in the off treatment interval
Study: NCT01999257

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online pre-test genetic education tool
Description: See Arm Descriptions above.